Compare Phillips 66 (PSX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs TG Therapeutics Inc — how do they compare? Phillips 66 trades at $278 (market cap $112.36B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Phillips 66 is far larger — about 13.8× TG Therapeutics Inc's market cap, and Phillips 66 pays a 1.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and TG Therapeutics Inc for 16 Days on average.
| PSX | TGTX | |
|---|---|---|
Market Cap | $112.36B | $8.16B |
Volume | 2,374,751 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $281.60 | $59.06 |
52-Week Low | $126.76 | $26.94 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $128.83B | $8.37B |
Dividend Yield | 1.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $278.18, up 2.42% with strong technical momentum as it approaches resistance near $280. The stock shows robust fundamentals with a P/E of 16.07 and ROE of 24.02%, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI-driven operational improvements, while analyst consensus remains bullish with a $279 price target.
PSX offers attractive valuation metrics and strong profitability, though revenue declines from 2022-2025 present headwinds. Key risks include refining margin volatility and potential diesel export restrictions. With institutional support and positive earnings trajectory, the stock presents a compelling opportunity for value-oriented investors despite cyclical industry exposure.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
